Active substance
Acetazolamide
- SFDA 6
- US FDA 43
- Health Canada 2
- US price lines 3
- NHS prices 1
- WHO EML 1
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Acetazolamide | 250 mg | Tablet · Oral use | 30 Blister | SAR 17.05 | Generic · Prescription | REMEDICA | Valid |
| DIAMOX 250MG TAB. | 250 mg | Tablet · Oral use | 25 Blister | SAR 19.65 | Generic · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| DIAMOX SUSTETS 500 MG | 500 mg | Capsule · Oral use | 100 Tablet Container | SAR 77.45 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| DIAMOX SUSTETS 500 MG | 500 mg | Capsule · Oral use | 30 Tablet Container | SAR 26.55 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| DIAMOX TAB 125MG | 125 mg | Tablet · Oral use | 100 Tablet Container | SAR 38.15 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| DIAMOX VIALS 500 MG | 500 mg | Injection · Parenteral use | 1 Vial | SAR 16.30 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
NON-INFECTIOUS UVEITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ACETAZOLAMIDE | 250MG | tablet · oral | CHARTWELL MOLECULAR | Prescription | 31 Mar 1978 |
| ACETAZOLAMIDE SODIUM | EQ 500MG BASE/VIAL | injectable · injection | HIKMA PHARMS | Prescription | 28 Feb 1995 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | TARO | Prescription | 28 May 1997 |
| ACETAZOLAMIDE SODIUM | EQ 500MG BASE/VIAL | injectable · injection | XGEN PHARMS | Prescription | 10 Dec 2008 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | HERITAGE PHARMA | Prescription | 10 Dec 2008 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | INDICUS PHARMA | Prescription | 14 Jul 2011 |
| ACETAZOLAMIDE SODIUM | EQ 500MG BASE/VIAL | injectable · injection | MYLAN ASI | Prescription | 9 May 2012 |
| ACETAZOLAMIDE SODIUM | EQ 500MG BASE/VIAL | injectable · injection | AVET LIFESCIENCES | Prescription | 19 Dec 2014 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | MPP PHARMA | Prescription | 29 Mar 2016 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | NOVAST LABS | Prescription | 30 Sep 2016 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | HERITAGE PHARMA | Prescription | 27 Oct 2016 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | STRIDES PHARMA | Prescription | 20 Nov 2017 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | ACCORD HLTHCARE | Prescription | 18 Oct 2018 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | CADILA | Prescription | 16 Jan 2019 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | ALEMBIC | Prescription | 19 Feb 2019 |
| ACETAZOLAMIDE SODIUM | EQ 500MG BASE/VIAL | injectable · injection | ZYDUS PHARMS | Prescription | 15 Apr 2019 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | NOVITIUM PHARMA | Prescription | 17 Oct 2019 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | ADAPTIS | Prescription | 18 Oct 2019 |
| ACETAZOLAMIDE | 500MG | capsule, extended release · oral | MICRO LABS LTD INDIA | Prescription | 1 Oct 2020 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | MANKIND PHARMA | Prescription | 7 Oct 2020 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | SOMERSET THERAPS LLC | Prescription | 22 Feb 2021 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | RUBICON RESEARCH | Prescription | 19 Aug 2021 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 4 Apr 2023 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | NE RX PHARMA | Prescription | 9 May 2023 |
| ACETAZOLAMIDE | 125MG; 250MG | tablet · oral | EPIC PHARMA LLC | Prescription | 14 May 2024 |
18 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACETAZOLAMIDE | 00545015 | 250 MG | TABLET · ORAL | AA PHARMA INC |
| ACETAZOLAMIDE FOR INJECTION USP | 02537893 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | MARCAN PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ACETAZOLAMIDE 125 MG TABLET | $0.09649 | per EA | 23 Sep 2026 |
| US NADAC | ACETAZOLAMIDE 250 MG TABLET | $0.13397 | per EA | 23 Sep 2026 |
| US NADAC | ACETAZOLAMIDE ER 500 MG CAP | $0.28822 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Acetazolamide 250mg tablets | £9.80 | 112 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 21.4. Ophthalmological preparations > Miotics and antiglaucoma medicines · core
Primary open-angle glaucoma
Oral > Solid: 250 mg
Safety signals and safety-related labeling changes
- EMA PRAC 11 Jul 2024 PRAC signal: Pulmonary oedemas
Action for MAH: update of the product information: Yes - EMA PRAC 7 Mar 2024 PRAC signal: Pulmonary oedemas
Action for MAH: update of the product information: No - EMA PRAC 31 Aug 2023 PRAC signal: Choroidal effusion and choroidal detachment
Action for MAH: update of the product information: Yes - EMA PRAC 14 Apr 2023 PRAC signal: Choroidal effusion and choroidal detachment
Action for MAH: update of the product information: No - EMA PRAC 29 Sep 2017 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: Yes - EMA PRAC 5 May 2017 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.